Richard Mcgregor Email & Phone Number

Princeton, Nj, Us

Princeton, Nj, Us

Led Business Development for KBP Biosciences (https://www.kbpbiosciences.com/), a global, clinical stage biopharmaceutical company focused on the development of an innovative pipeline of new chemical entities with known mechanisms of action targeting underserved patient populations in organ protection and infectious diseases. KBP utilizes an integrated discovery and development platform that enables the Companyto efficiently bring new therapies from bench to patients around the world.In October 2023, Novo Nordisk acquired our lead product candidate, Ocedurenone, for up to $1.3 Billion (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166329). Ocedurenone (https://www.kbpbio.com/index.php?c=show&id=26), is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a potentially best-in-class safety and efficacy profile. It is in Phase 3 clinical development for the treatment of uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who have high risk of hyperkalemia.KBP is also developing Zifanocycline (https://www.kbpbio.com/index.php?c=show&id=25), a Phase 2 ready third-generation aminomethylcycline for the treatment of multiple strains of drug-resistant infections with high activity against certain key pathogens.KBP has built a proprietary R&D platform aimed at the discovery and development of global first-in-class compounds. The platform includes a compound library which is the basis of new compound discovery, a bacterium library aimed at multi-drug resistant bacteria, and an in vivo pharmacology platform for screening and testing new compounds. KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.

New York, New York, Us

Driving the successful execution of JDRF’s research strategy by identifying, evaluating, and implementing external project and partnership opportunities in alignment with JDRF’s objectives.- Acting as an internal “entrepreneur” to:(i) Identify and evaluate internal and external opportunities(ii) Define and grow areas of strategic focus within JDRF’s priorities(iii) Find creative ways to advance programs through partnering(iv) Provide leadership to partnered projects

Brentford, Middlesex, Gb

Core member of the Consumer Healthcare R&D Open Innovation team, and category Portfolio Management Boards. Developed, led, and executed category-specific external innovation strategies. Maintained strong relationships with a network of key vendors, collaborators, and potential partners. Primary point of contact with external innovation partners, leading due diligence of technologies.

Brentford, Middlesex, Gb

Used robust external search and evaluation approaches to identify breakthrough technologies. Developed and led internal program of GSK staff in various functions and locations, tasked with identifying technologies in their local regions (Global Technology Scout program). Increased awareness of GSK Open Innovation, and it’s status as partner-of-choice by presenting at industry, academic, and Open Innovation conferences.

Reporting directly to the CEO, developed new business relationships with external partners, and identified and negotiated in-licensing of technology essential to company’s growth. Alliance manager and member of steering committee for all external agreements.Scientific representative in negotiations with business and academic partners, and venture capitalists. Planned, budgeted, and wrote collaboration proposals. Led regulatory affairs program.

Phd, Biochemistry And Molecular Biology

Bsc. (Hons), Biochemistry